1. Scrip
  2. >>Business
  3. >>Strategy

Teva/Sanofi’s Phase IIb Data In IBD Look Competitive Vs. Merck, Roche

 
• By Joseph Haas

Teva reported Phase IIb data for its anti-TL1A agent in ulcerative colitis and Crohn’s that the company called transformational and analysts deemed potentially best in class.

Teva logo outside building
Teva reported strong Phase IIb data for its anti-TL1A agent in IBD indications • Source: Shutterstock

Teva and Sanofi unveiled positive Phase IIb data on 17 December for the TL1A-targeting antibody candidate they are developing to compete against candidates from the same class at Roche and Merck & Co. in inflammatory bowel disease (IBD). On a same-day call, Teva execs asserted that their drug, duvakitug (TEV‘574/SAR447189), has produced “transformational” data in both ulcerative colitis and Crohn’s disease as the partners look ahead to planning a Phase III program.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Therapy Areas

In Brief: DIOSynVax And ACM Biolabs To Develop Bird Flu Vaccine

 
• By Sushmita Panda

The collaboration, supported by UK and Singapore government agencies, aims to develop an mRNA-based, needle-free universal bird flu vaccine suitable for use in a pandemic.

MetaVia’s ‘Safe’ Obesity Drug Resonates With Analysts, But Not Investors

 
• By Joseph Haas

The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.

In Brief: US FDA Rejects Regeneron’s Bid to Extend Eylea HD Dosing

 
• By Sushmita Panda

Regeneron is disappointed by the knock-back for longer dosing intervals for its high-dose version of Eylea, but its supplemental application for a more commercially important shorter four-week regimen has received a priority review.